Who Qualifies for a GLP-1—and Who Should Not Take One

Eligibility for a GLP-1 medicine depends on the actual product, the condition being treated, your age, and your medical history. Meeting a weight threshold is a starting point for assessment, not automatic approval for every formulation or a guarantee that insurance will pay.

This guide focuses on weight-management treatment while separating other approved indications. The current labels include more than the original weekly-injection options, so a clinician should identify the exact medicine before applying an eligibility checklist.

Adult weight-management thresholds

Common adult thresholds for considering prescription weight-management medicine are BMI 30 or higher, or BMI 27 or higher with a weight-related health problem, such as high blood pressure or type 2 diabetes.¹ BMI is a screening measure; the clinical discussion also needs your health history, goals, and prior treatment.

Wegovy, Zepbound, and Foundayo have weight-management indications for adults with obesity or overweight accompanied by a weight-related condition, alongside diet and physical activity.²³⁴ That does not make them interchangeable prescriptions. A provider should explain why the selected product is appropriate and how response and tolerability will be reviewed.

Our semaglutide-versus-tirzepatide comparison explains the direct trial evidence without using group averages as a promise about your result.

Age and other indications change the answer

Wegovy injection has a weight-management indication for patients aged 12 and older with obesity; pediatric eligibility uses age- and sex-specific assessment, not simply the adult BMI cutoff. Wegovy tablets have adult indications. Pediatric use is not established for Wegovy HD 7.2 mg, Zepbound, or Foundayo.²³⁴

Other conditions have their own criteria. Zepbound treats moderate-to-severe obstructive sleep apnea in adults with obesity. Wegovy has cardiovascular-risk-reduction indications in adults with established cardiovascular disease and overweight or obesity; its injection also has an indication for particular noncirrhotic MASH with fibrosis, under accelerated approval.²³

The sleep-apnea guide covers that specific indication. Do not assume a product approved for one condition or age group is approved for all related conditions, forms, or ages. Diabetes-branded medications also have their own labels rather than sharing a single generic GLP-1 eligibility rule.

Contraindications are product-specific exclusions

The Wegovy, Zepbound, and Foundayo labels contraindicate use in people with a personal or family history of medullary thyroid carcinoma, or MEN 2. They also list hypersensitivity to the relevant drug or ingredients as a contraindication.²³⁴

Medullary thyroid carcinoma is a specific cancer type. Do not interpret the warning as an identical rule for every thyroid diagnosis, or assume thyroid-replacement treatment alone answers the eligibility question. Bring the actual diagnosis and medication list. Our thyroid-warning guide explains the distinction and the uncertainty behind the boxed warning.

A previous severe allergic reaction needs clinical review of the precise product and ingredients; an online eligibility form cannot resolve that history safely.

Precautions need a fuller assessment

Tell the clinician about pancreatitis or gallbladder problems, significant digestive disease, kidney problems or dehydration, diabetes treatment, and existing eye disease. These facts can change monitoring, suitability, or the alternatives considered. Severe gastroparesis is specifically addressed in current labeling; it should not be reduced to a routine nausea checkbox.²³⁴

The gastroparesis guide separates ordinary symptoms from a diagnosis. Report persistent constipation or vomiting too, particularly before a planned dose increase. Our constipation article explains why warning symptoms deserve assessment rather than an automatic refill.

If you take insulin, a sulfonylurea, oral contraception, or other medicines, use the interaction guide to prepare a complete list. Oral products can have distinct interaction and administration requirements.

A new skin symptom after treatment also needs its own assessment. Our semaglutide injection-site reaction guide explains why a local red patch alone does not establish serious hypersensitivity and which warning signs require emergency care.

Pregnancy, breastfeeding, and procedures

Discuss pregnancy plans and breastfeeding before prescribing; recommendations differ by product and formulation. For weight management, these medicines should not be treated as pregnancy treatments. Wegovy has a specific preconception discontinuation interval, and its tablet lactation advice differs from the considerations for injection.² Our pregnancy guide explains why a clinician should plan that transition.

An upcoming procedure is a reason to coordinate care, not an automatic permanent exclusion. Current multisociety anesthesia guidance uses individualized assessment, with most patients able to continue treatment; symptoms and other risks may change the plan.⁵ Read the surgery guide and notify the anesthesia and prescribing teams early. Do not choose a hold interval from a generic eligibility page.

Clinical eligibility, coverage, and service acceptance differ

An insurer can have additional documentation or coverage rules. A telehealth service may limit ages, conditions, formulations, or states even when a medicine has a broader approval. Ask which limitation applies instead of assuming rejection means no medically appropriate option exists.

Our provider checklist helps assess clinician access and the quality of the intake. A useful assessment explains the indication, exclusions, precautions, follow-up, and realistic access—not just whether a checkout form accepts your BMI.

Once treatment is prescribed, the Zepbound response timeline explains why early results do not determine eligibility or justify changing a dose independently.